Oncolytics reports faster enrollment in REO 033 colorectal cancer study
Nearly all Part A sites are active, an interim update is expected by year-end 2026, and the FDA has aligned on a possible accelerated approval route.
SEC filing (2)
Latest
3 stories
Yesterday
Tuesday, August 18
Oncolytics gets FDA feedback on pivotal path for pelareorep in colorectal cancer
The FDA's written response addresses a possible accelerated approval route for REO 033's Part B expansion in second-line RAS-mutant MSS metastatic colorectal cancer.
SEC filing
Monday, July 20
Oncolytics wins FDA Fast Track for pelareorep in second-line anal cancer
The designation applies to pelareorep paired with a checkpoint inhibitor in advanced anal cancer patients whose disease progressed after prior treatment.
SEC filing